Spyre Therapeutics, Inc. SYRE Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Spyre Therapeutics, Inc. (SYRE) reported accretion (amortization) of discounts and premiums, investments of $2.06M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Spyre Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 22.1% year-over-year, from $2.64M to $2.06M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 96.0% compound annual growth rate (CAGR), from -$548K to $8.09M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to the carrying value of debt or investment securities purchased at a discount or premium. Over time, the discount or premium is amortized or accreted to reach the face value of the instrument at maturity. It is a standard adjustment to reconcile interest income or expense to actual cash flows.